F. Stelma

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Meike H. van der Ree, J. Marleen de Vree, F. Stelma et al. · The Lancet · 2017 · 268 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Human intrahepatic CD69 + CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity

F. Stelma, A. de Niet, Marjan J. Sinnige et al. · Scientific Reports · 2017 · 106 citations · Full text

Medicine, Immunology, Pathology +17

Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir

F. Stelma, A. de Niet, Marjan J. Tempelmans Plat-Sinnige et al. · The Journal of Infectious Diseases · 2015 · 54 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101

F. Stelma, Meike H. van der Ree, Marjan J. Sinnige et al. · Hepatology · 2017 · 53 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial

A. de Niet, Louis Jansen, F. Stelma et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 51 citations

Pharmacy, Internal Medicine, Pharmacotherapy +14